RCP
JBIO

Remedium Capital Partners’s Jade Biosciences JBIO Stock Holding History

Remedium Capital Partners’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.1M Hold
1,577,750
– – 7.76% 5
2026
Q1 		$22.2M Hold
1,577,750
– – 7.88% 5
2025
Q4 		$24.3M Buy
+1,577,750
New +$18.5M 14.3% 4

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Remedium Capital Partners's JBIO Position: Q2 2026 in Review

Remedium Capital Partners held its Jade Biosciences (JBIO) position steady in Q2 2026 at 1,577,750 shares worth $35.1M. The position accounts for 7.76% of the portfolio, ranked #5.

Remedium Capital Partners first reported a position in JBIO in Q4 2025 and has held it in 3 quarters since. 154 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • Remedium Capital Partners held 1,577,750 shares of Jade Biosciences worth $35.1M as of Q2 2026.
  • Remedium Capital Partners left its Jade Biosciences share count unchanged in Q2 2026.
  • Jade Biosciences made up 7.76% of Remedium Capital Partners's portfolio in Q2 2026, its #5 holding.
  • Remedium Capital Partners first reported a position in Jade Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 154 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Remedium Capital Partners's 13F filing for Q2 2026, filed 7 Aug 2026.